Grifols’ Biotest launches Yimmugo immunoglobulin therapy in US market The US FDA approved the intravenous immunoglobulin (IVIg) therapy for the treatment of primary immunodeficiencies (PID) last year.

Grifols and Biotest have launched Yimmugo in the US. The FDA-approved intravenous immunoglobulin (IVIg) provides a new treatment option for individuals with primary immunodeficiencies (PID), expanding access to critical care.

#News #Yimmugo #Immunodeficiency #PID #RareDisease #FDAapproved

Grifols’ Biotest launches Yimmugo immunoglobulin therapy in US market The US FDA approved the intravenous immunoglobulin (IVIg) therapy for the treatment of primary immunodeficiencies (PID) last year.

Grifols and Biotest have launched Yimmugo in the US. The FDA-approved intravenous immunoglobulin (IVIg) provides a new treatment option for individuals with primary immunodeficiencies (PID), expanding access to critical care.

#News #Yimmugo #Immunodeficiency #PID #RareDisease #FDAapproved

YIMMUGO® Launches in the U.S.: A New Treatment for Primary Immunodeficiency Kedrion Biopharma announces the U.S. launch of YIMMUGO, a new immunoglobulin therapy for primary immunodeficiency patients, enhancing treatment options.

YIMMUGO® Launches in the U.S.: A New Treatment for Primary Immunodeficiency #United_States #Fort_Lee #Primary_Immunodeficiency #Kedrion_Biopharma #YIMMUGO